<DOC>
	<DOCNO>NCT00680628</DOCNO>
	<brief_summary>The purpose study determine tenecteplase plus enoxaparin safe effective treatment patient severe submassive pulmonary embolism .</brief_summary>
	<brief_title>Clot Dissolving Treatment Blood Clots Lungs</brief_title>
	<detailed_description>This project phase III , six-center , randomize trial tenecteplase treat severe submassive ( systolic blood pressure &gt; 90 mm Hg ) pulmonary embolism ( PE ) . `` Severe '' require one follow predictor adverse outcome : right ventricular ( RV ) hypokinesis echocardiography , hypoxemia ( pulse oximetry read &lt; 95 % , &lt; 1000 foot sea level ) , serum troponin I ( abnormal local threshold ) brain natriuretic peptide concentration &gt; 90 pg/mL ( NT proBNP &gt; 900 pg/mL ) . Patients emergency department inpatient enrol within 24 hour diagnostic positive CT angiography . After informed consent , eligible patient randomize study placebo arm . All patient receive 1mg/kg enoxaparin , SQ follow syringe prepared pharmacy contain either body weight-adjusted dose tenecteplase 0.9 % saline placebo , give IV push . Patients follow five day post-treatment composite acute adverse outcome : PE-related ( death , ACLS intervention , circulatory shock , respiratory failure , need vasopressor organ dysfunction ) hemorrhage-related ( intracranial intraspinal hemorrhage hemorrhage require transfusion , surgical endoscopic intervention hemostatic drug ) . Survivors return three month assessment delayed adverse outcome death cardiopulmonary functional limitation ( CFL ) : interval medical care dyspnea + RV dysfunction pulmonary hypertension echo + either NYHA score ≥3 6 minute walk distance &lt; 330 m. Together , acute delay outcome represent composite serious adverse outcome ( SAOs ) . We hypothesize absolute 20 % reduction composite serious adverse outcome study arm compare placebo arm . The six hospital represent geographic diversity : Boston , Charlotte , Chicago , Denver , New Haven , Springfield , MA . To help maintain balance site , six site enroll maximum 40 patient sample size N=200 reach , allow 20 % effect size test α =0.05 β=0.20 15 % loss follow-up . The study employ intent-to treat analysis . Secondary endpoint include recurrent venous thromboembolism within three month , score two validate quality life questionnaire ( VEINES-QOL SF-36TM ) three month . Human subject safety include requirement study MD verify presence inclusion absence exclusion real-time , method allow unblinding clinical care team , independent DSMB perform 6 interim analysis enforce predefined stop criterion either safety efficacy .</detailed_description>
	<mesh_term>Embolism</mesh_term>
	<mesh_term>Pulmonary Embolism</mesh_term>
	<mesh_term>Tenecteplase</mesh_term>
	<mesh_term>Tissue Plasminogen Activator</mesh_term>
	<criteria>Pulmonary vascular image positive PE within previous 24 hour Ability provide write informed consent comply study assessment full duration study Age &gt; 17 year Evidence severe PE : RV hypokinesis echocardiography , abnormal troponin I T ( nonnormal include indeterminate value , use local reference threshold ) BNP measurement &gt; 90 pg/mL NT proBNP &gt; 900 pg/ml ( 6 hour prior CT angiography 30 hour enrollment ) pulse oximetry read &lt; 95 % within previous two hour ( &lt; 93 % Denver ) . Systolic blood pressure &lt; 90 mm Hg time inform consent Do resuscitate intubate order Systemic fibrinolytic treatment within previous 7 day Inability followup 3 month Documented gastrointestinal bleeding within previous 30 day Active hemorrhage follow site time enrollment : intraperitoneal , retroperitoneal , pulmonary , uterine , bladder , nose . Head trauma cause loss consciousness within previous 7 day Any history hemorrhagic stroke Ischemic stroke within past year Prior history heparininduced thrombocytopenia History intraocular hemorrhage Intracranial metastasis Known inherit bleed disorder , e.g. , hemophilia Platelet count &lt; 50,000/uL Prothrombin time INR &gt; 1.7 Chest , abdominal , intracranial spinal surgery within previous 14 day Subacute bacterial endocarditis Pregnancy ( positive pregnancy test ) Prior enrollment study Current treatment fondiparinux , dalteparin , direct thrombin inhibitor administration glycoprotein inhibitor within previous 48 hour . Known pericarditis Allergy heparin , tenecteplase Elapsed time would preclude drug placebo administration within 24 hour diagnosis Evidence nonend stage kidney injury ( creatinine clearance &lt; 30 ml/min without chronic hemodialysis treatment ; chronic hemodialysistreated patient eligible ) Preexisting endstage cardiopulmonary disease ( heart failure leave ventricular ejection fraction &lt; 20 % , know severe pulmonary hypertension lung disease cause permanent dependence upon oxygen ) Any condition investigator believe would pose significant hazard subject</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>Pulmonary Embolism</keyword>
	<keyword>Tenecteplase</keyword>
	<keyword>Enoxaparin</keyword>
	<keyword>Thrombosis</keyword>
	<keyword>Fibrinolytics</keyword>
</DOC>